Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung BioLogics and Biogen formed in 2012.